Instructions for Angelica Micro (Estradiol, Drospirenone) 28 pills
English product name
Angelica® Micro
Release form
tab, film coating, 0.25 mg+0.5 mg: 28 or 84 pcs
Description Angelica Micro:
The tablets are covered with a yellow film shell, round, double-convex, with "EL" embossed in a regular hexagon on one side.
1 tab.
drospirenone (micronized) 0.25 mg
estradiol (in the form of estradiol hemihydrate, micronized) 0.5 mg
Auxiliary substances:
lactose monohydrate - 50.45 mg,
corn starch - 14.4 mg,
corn starch pregelatinized - 9.6 mg,
povidone - 4 mg,
magnesium stearate - 0.8 mg.
Shell Composition Angelica Micro:
lacquer yellow - 2 mg:
hypromellose (5 cP) - 1.0112 mg,
macrogol 6000 - 0.2024 mg,
talc - 0.2024 mg,
titanium dioxide - 0.464 mg,
iron oxide yellow - 0.12 mg.
28 pcs. - blister packs (1) with blister pockets - cardboard packs with first-opening control.
28 pcs. - blister packs (3) with blister pockets - cardboard packs with first-opening control.
ATC codes
G03FA17 Drospirenone and Estrogen
Clinical-pharmacological groups / Group affiliation
Anticlimacteric combined drug (estrogen+gestagen)
Active substance
estradiol (in the form of hemihydrate, micronized)
drospirenone (micronized)
Pharmacotherapy group Angelica Micro:
Anticlemacteric compound (estrogen+progestagen)
Storage Conditions
The drug should be stored in a place inaccessible to children at a temperature not higher than 30 ° C.
Best before date
The shelf life is three years. Do not apply after the expiry date indicated on the package.
Testimony Angelica Micro:
- hormone replacement therapy for the treatment of moderate to severe vasomotor symptoms associated with menopause
- in women with non-distant uterus.
Method of use, course and dosage:
If a woman does not take estrogen or switches to Angelica® Micro from another combination drug for continuous use, she can start treatment at any time.
Patients who switch to Angelica® Micro with a combination drug for cyclic GST should start taking after the end of the current cycle of therapy.
Each package is designed for a 28-day reception.
You should take 1 tablet every day. After taking 28 tablets from the current package, the next day the pill is taken from the new package of Angelica® Micro (continuous CGT), taking the first tablet on the same day of the week as the first tablet from the previous package.
The tablet is swallowed whole, washed down with a small amount of liquid. Tablets are taken regardless of the intake of food. The time of day when a woman takes the drug is irrelevant, but if she starts taking the pill at any given time, she should stick to that time and go on. The forgotten pill must be taken as soon as possible. If more than 24 hours have passed after the usual time of taking, no additional pill should be taken. If several tablets are missed, vaginal bleeding may develop.
The use of the drug is contraindicated in children and adolescents under 18 years of age.
Elderly patients: There is no evidence of dose correction in women under 65. When using the drug Angelica® Micro in women over 65 years of age should take into account the information provided in the subsection "Dementia" of the section "Special instructions".
Terms of implementation
The drug is dispensed by prescription.
Use in elderly patients
There is no evidence of the need for dose adjustment in women under 65 years of age.
There is limited evidence from clinical studies on a possible increased risk of dementia in women starting CVE-containing drugs aged 65 years and older.
Use in children
The drug is contraindicated for use in children and adolescents under 18 years of age.
- Nosology Angelica Micro (ICD codes)
- N95.1
- Menopause and menopause in women
- N95.3
- Conditions associated with artificially induced menopause
Pharmacological effect Angelica Micro:
The drug Angelica Micro contains 17β-estradiol, chemically and biologically identical to human endogenous estradiol, and synthetic progestagen, drospirenone. 17β-estradiol provides estrogen replacement in the female body during and after menopause. The addition of drospirenone ensures the control of bleeding and prevents the development of estrogen-induced endometrial hyperplasia.
Estradiol effects:
A decline in ovarian function, accompanied by a decrease in estrogen and progestogen production in the body, leads to the development of menopausal syndrome, characterized by vasomotor and organic symptoms. Hormone replacement therapy (SGT) is shown to treat these symptoms.
Of all natural estrogens, estradiol is the most active and has the most affinity (binding force) for estrogen receptors. The target organs for estrogens are, in particular, the uterus, the hypothalamus, the pituitary, the vagina, the mammary glands, the bones (namely, the cells of the osteoclasts).
